Skip to content
Other Publications (35)
- Brachytherapy
- Technology in Cancer Research & Treatment
- Journal of Oncology
- Radiation Research
- Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
- Radiation Research
- International Journal of Radiation Oncology, Biology, Physics
- Gynecologic Oncology
- International Journal of Radiation Oncology, Biology, Physics
- Radiation Research
- International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
- Obstetrics and Gynecology International
- Gynecology & Obstetrics (Sunnyvale, Calif.)
- Journal of Nuclear Medicine & Radiation Therapy
- Nucleosides, Nucleotides & Nucleic Acids
- Future Oncology (London, England)
- International Journal of Radiation Oncology, Biology, Physics
- Oncology & Hematology Review
- International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
- Cancers
- Frontiers in Oncology
- International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
- Expert Review of Anticancer Therapy
- Gynecologic Oncology
- Frontiers in Oncology
- Current Opinion in Oncology
- Frontiers in Oncology
- International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
- Future Oncology (London, England)
- Discovery Medicine
- Frontiers in Oncology
- The Breast Journal
- International Journal of Radiation Oncology, Biology, Physics
- Methods in Molecular Biology (Clifton, N.J.)
- Biomedical Chromatography : BMC
Articles by Charles A. Kunos in JoVE
-
ديناميكية الرئة تتبع ورم لالمجسم صيغة الجر الجسم العلاج الإشعاعي
Charles A. Kunos1, Jeffrey M. Fabien1, John P. Shanahan1, Christine Collen2, Thierry Gevaert2, Kenneth Poels2, Robbe Van den Begin2, Benedikt Engels2, Mark De Ridder2
1Department of Radiation Oncology, Summa Cancer Institute, 2Department of Radiation Oncology, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel
Other articles by Charles A. Kunos on PubMed
-
-
-
Radiation Therapy in Addition to Gross Total Resection of Retroperitoneal Sarcoma Results in Prolonged Survival: Results from a Single Institutional Study
Journal of Oncology.
2008 |
Pubmed ID: 19277103 Purpose. Typical treatment of retroperitoneal sarcomas (RPSs) is surgery with or without radiation therapy for localized disease. With surgery alone, local failure rates are as high as 90%; this led to radiation therapy playing an important role in the treatment of RPSs. Methods. Thirty-one patients with retroperitoneal sarcoma treated with gross total resection and radiation therapy make up this retrospective analysis. Nineteen were treated preoperatively and 12 postoperatively (median dose, 59.4 Gy)-sixteen also received intraoperative radiation therapy (IORT) (median dose, 11 Gy). Patients were followed with stringent regimens, including frequent CT scans of the chest, abdomen, and pelvis. Results. With a median follow-up of 19 months (range 1-66 months), the 2-year overall survival (OS) rate is 70% (median, 52 months). The 2-year locoregional control (LRC) rate is 77% (median, 61.6 months). The 2-year distant disease free survival (DDFS) rate is 70% (median not reached). There were no differences in radiation-related acute and late toxicities among patients treated pre- versus postoperatively, whether with or without IORT. Conclusions. Compared to surgery alone, neoadjuvant or adjuvant radiation therapy offers patients with RPS an excellent chance for long-term LRC, DDS, and OS. The integration of modern treatment planning for external beam radiation therapy and IORT allows for higher doses to be delivered with acceptable toxicities.
-
Modulating Radiation Resistance by Inhibiting Ribonucleotide Reductase in Cancers with Virally or Mutationally Silenced P53 Protein
Radiation Research.
Dec, 2009 |
Pubmed ID: 19929413 Therapeutic ionizing radiation damages DNA, increasing p53-regulated ribonucleotide reductase (RNR) activity required for de novo synthesis of the deoxyribonucleotide triphosphates used during DNA repair. This study investigated the pharmacological inhibition of RNR in cells of virally or mutationally silenced p53 cancer cell lines using 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine(R), NSC #663249), a chemotherapeutic radiosensitizer that equally inhibits RNR M2 and p53R2 small subunits. The effects of 3-AP on RNR inhibition and resulting radiosensitization were evaluated in cervical (CaSki, HeLa and C33-a) and colon (RKO, RKO-E6) cancer cells. 3-AP treatment significantly enhanced radiation-related cytotoxicity in cervical and colon cancer cells. 3-AP treatment significantly decreased RNR activity, caused prolonged radiation-induced DNA damage, and resulted in an extended G(1)/S-phase cell cycle arrest in all cell lines. Similar effects were observed in both RKO and RKO-E6 cells, suggesting a p53-independent mechanism of radiosensitization. We conclude that inhibition of ribonucleotide reductase by 3-AP enhances radiation-mediated cytotoxicity independent of p53 regulation by impairing repair processes that rely on deoxyribonucleotide production, thereby substantially increasing the radiation sensitivity of human cancers.
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get cutting-edge science videos from JoVE sent straight to your inbox every month.